TG Therapeutics Reports 69.7% Revenue Growth to $204.9 Million in Latest Quarter

TG Therapeutics, Inc. reported significant financial growth in its latest quarterly results, with total revenue reaching $204.9 million for the three months ended March 31, 2026, compared to $120.9 million for the same period in 2025. This represents an increase of approximately 69.7%. The surge in revenue was primarily driven by product sales of BRIUMVI (ublituximab), which accounted for $201.3 million, up from $119.7 million year-over-year. The company also recognized $3.6 million in license, milestone, and royalty revenue, reflecting a substantial increase from $1.2 million in the prior year.

The company's operating income for the first quarter of 2026 was reported at $34.8 million, a notable rise from $8.6 million in the same quarter of the previous year. Net income for the period was $19.8 million, or $0.14 per share, compared to $5.1 million, or $0.03 per share, in the prior year. This improvement in profitability is attributed to increased market penetration of BRIUMVI and effective cost management, despite a rise in total costs and expenses, which increased to $170.1 million from $112.2 million.

In terms of strategic developments, TG Therapeutics has made significant strides in its commercialization efforts. The company entered into a new five-year, $750 million senior secured credit facility with Blue Owl Capital, which allowed it to repay an existing $250 million loan and raise an additional $500 million in non-dilutive capital. This financing is expected to support ongoing commercialization activities and future product development. Additionally, the Board of Directors authorized an increase in the share repurchase program from $100 million to $300 million, reflecting confidence in the company's financial position.

Operationally, TG Therapeutics has focused on expanding its commercial infrastructure and enhancing its product offerings. The company is actively pursuing the development of a subcutaneous formulation of BRIUMVI, with a Phase 3 trial recently completing enrollment. Furthermore, the company has entered into a commercialization agreement with Neuraxpharm for BRIUMVI in certain territories outside the U.S., which is expected to contribute to future revenue growth. As of March 31, 2026, the company reported an accumulated deficit of approximately $1.1 billion, but it maintains a strong cash position with $572.8 million in cash and cash equivalents and investment securities.

Looking ahead, TG Therapeutics anticipates continued revenue growth driven by the ongoing commercialization of BRIUMVI and the potential launch of additional product candidates. The company expects to incur significant research and development expenses as it expands its clinical programs and pursues new therapeutic opportunities. Management believes that existing cash reserves, along with projected revenues, will be sufficient to fund operations for at least the next twelve months, although future capital requirements may necessitate additional financing.